On September 18, 2026 Alaunos Therapeutics, Inc. (Nasdaq: TCRT) reported that it has entered into definitive agreements with institutional investors in a registered direct offering for the sale of 380,469 shares of its common stock and pre-funded warrants to purchase up to 386,654 shares of common stock at a price of $1.46 per share, for aggregate gross proceeds of approximately $1,120,000, before deducting placement agent fees and offering expenses. The offering was priced at-the-market under Nasdaq rules. The offering is expected to close on or about September 21, 2026, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company intends to use the net proceeds from the offering primarily for general working capital and corporate purposes.

Dawson James Securities, Inc. is acting as sole placement agent for the offering.

The securities will be offered and sold pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289748), including a base prospectus, initially filed with the U.S. Securities and Exchange Commission (the "SEC") on November 11, 2025 and became effective on December 1, 2025. The offering will be made only by means of a written prospectus. A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of Dawson James Securities, Inc. 2700 N Military Trail, Suite 100, Boca Raton, FL, 33431 or by email at [email protected].

Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Alaunos Therapeutics, SEP 18, 2026, View Source [SID1234671031])